74 filings
Page 3 of 4
8-K
9ixhx94e3 hz
31 Jul 20
Other Events
5:02pm
8-K
d8hzwldnzlkdbkr mfxe
30 Jul 20
Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies
6:43am
8-K
srb yhnlelz0owy
25 Jun 20
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
3yei8zdodtbe821n7j
13 Apr 20
Entry into a Material Definitive Agreement
9:01am
8-K
bwc5g03w
29 Jan 20
Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV
9:15am
8-K
z6w3 cmx9mkt
26 Dec 19
Other Events
7:08am
8-K
irhvd9mpl w075r2
17 Oct 19
Other Events
9:15am
8-K
l9odrg
4 Sep 19
Spring Bank Announces $20 Million Strategic Debt Financing Agreement with Pontifax Medison Finance
8:30am
8-K
dhursh91
10 Jul 19
Spring Bank Pharmaceuticals Announces Election of Pamela Klein, M.D., to its Board of Directors
4:15pm
8-K
685mdiv4uhy 79qu1b
12 Apr 19
Regulation FD Disclosure
8:00am
8-K
sc70icluf18biv
18 Dec 18
Departure of Directors or Certain Officers
4:15pm
8-K
5lqggp0c
6 Nov 18
Regulation FD Disclosure
8:01am
8-K
khd8j2q2
16 Aug 18
Spring Bank Pharmaceuticals, Inc. Appoints Scott Smith to its Board of Directors
4:00pm
8-K
u31tkklr8l3 mty
9 Aug 18
Spring Bank Announces Proposed Public Offering of Common Stock
12:00am
8-K
k6mi6
2 Aug 18
Regulation FD Disclosure
8:00am
8-K
z9mucqyf8z xny1
1 Aug 18
Spring Bank Pharmaceuticals Reports Second Quarter Financial Results
12:00am
8-K
qaxe uvbbexnxlmuf
19 Jun 18
Departure of Directors or Certain Officers
4:21pm
8-K
vclli3
27 Apr 18
Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter Financial and Operational Results
9:15am
8-K
hhao1gqe
25 Apr 18
Regulation FD Disclosure
9:15am
8-K
g42bvkzhp31r 0sem4lv
10 Apr 18
Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver CongressTM
12:00am